Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Urologic Oncology
In which patients are referring for focal gland therapy for localized prostate cancer?
Do you prefer HIFU or cryoablation? Do you use in newly diagnosed or post-RT recurrence, or both?
Related Questions
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
How can you manage a patient with bilateral PCNs who requires Pluvicto administration?
For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?
What chemotherapy regimen do you use for de novo metastatic squamous cell carcinoma of penile urethra?
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?